Tumor-associated antigen presented by major histocompatibility complex molecule

Tumor-associated antigens presented by major histocompatibility complex molecules are peptide fragments derived from proteins expressed or mutated in tumor cells. These peptides are processed and loaded onto MHC molecules (class I and II) within the cell and then displayed on the cell surface. This presentation allows T cells to discriminate between normal and malignant cells, facilitating immune surveillance and potential immune-mediated destruction of cancer cells. The ability of a tumor to evade immune destruction often involves defects in antigen processing or loss of MHC molecule expression, making the antigen-MHC complex a critical target and biomarker for cancer immunotherapies[1][3][4][5][6]. For structured data needs, further specification of the particular antigen or MHC allele is required, as the entry currently refers to a broad molecular interaction rather than a singular molecule or protein.

Other names

Tumor antigen-MHC complextumor peptide-MHC complexTAA-MHC

Enhancement of T cell recognition and killing of tumor cells presenting antigens via MHC I (CD8+ T cells); Activation of helper T cells via MHC II pathways (CD4+ T cells); Blocking immune evasion mechanisms such as loss of antigen presentation machinery